A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozorakimab (Primary)
Indications Lung disorders; Viral infections
Focus Registrational; Therapeutic Use
Acronyms TILIA
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

29 Jan 2025 Planned End Date changed from 17 Mar 2025 to 19 Jun 2026.
29 Jan 2025 Planned primary completion date changed from 17 Mar 2025 to 19 Jun 2026.
20 Nov 2024 Planned number of patients changed from 2902 to 2870.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight